JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 178 filers reported holding JUNO THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 1.38 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $359,000 | -43.9% | 7,860 | -44.9% | 0.45% | +423.3% |
Q3 2017 | $640,000 | +65.4% | 14,261 | +10.1% | 0.09% | +48.3% |
Q2 2017 | $387,000 | +11.5% | 12,957 | -17.2% | 0.06% | -6.5% |
Q1 2017 | $347,000 | +30.0% | 15,654 | +10.6% | 0.06% | -22.5% |
Q4 2016 | $267,000 | +47.5% | 14,153 | +135.2% | 0.08% | -9.1% |
Q3 2016 | $181,000 | -21.6% | 6,017 | 0.0% | 0.09% | -48.5% |
Q2 2016 | $231,000 | +13.2% | 6,017 | +12.4% | 0.17% | -39.1% |
Q1 2016 | $204,000 | – | 5,353 | – | 0.28% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |